Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
60.70 MXN
4.78 B MXN
14.08 B MXN
125.86 M
About Halozyme Therapeutics, Inc.
Sector
Industry
CEO
Helen I. Torley
Website
Headquarters
San Diego
Founded
1998
FIGI
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
HALO5387960
Halozyme Therapeutics, Inc. 0.25% 01-MAR-2027Yield to maturity
2.55%
Maturity date
Mar 1, 2027
HALO5638653
Halozyme Therapeutics, Inc. 1.0% 15-AUG-2028Yield to maturity
−1.25%
Maturity date
Aug 15, 2028
Explore more bonds
Curated watchlists where HALO is featured.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange HALOZYME THERAPEUTICS, INC stocks are traded under the ticker HALO.
HALO stock has fallen by −15.36% compared to the previous week, the month change is a −15.36% fall, over the last year HALOZYME THERAPEUTICS, INC has showed a −15.36% decrease.
We've gathered analysts' opinions on HALOZYME THERAPEUTICS, INC future price: according to them, HALO price has a max estimate of 1,545.75 MXN and a min estimate of 1,030.50 MXN. Watch HALO chart and read a more detailed HALOZYME THERAPEUTICS, INC stock forecast: see what analysts think of HALOZYME THERAPEUTICS, INC and suggest that you do with its stocks.
HALO stock is 18.15% volatile and has beta coefficient of 1.35. Track HALOZYME THERAPEUTICS, INC stock price on the chart and check out the list of the most volatile stocks — is HALOZYME THERAPEUTICS, INC there?
Today HALOZYME THERAPEUTICS, INC has the market capitalization of 127.10 B, it has decreased by −10.53% over the last week.
Yes, you can track HALOZYME THERAPEUTICS, INC financials in yearly and quarterly reports right on TradingView.
HALOZYME THERAPEUTICS, INC is going to release the next earnings report on Feb 25, 2025. Keep track of upcoming events with our Earnings Calendar.
HALO earnings for the last quarter are 25.02 MXN per share, whereas the estimation was 18.88 MXN resulting in a 32.57% surprise. The estimated earnings for the next quarter are 24.16 MXN per share. See more details about HALOZYME THERAPEUTICS, INC earnings.
HALOZYME THERAPEUTICS, INC revenue for the last quarter amounts to 5.72 B MXN, despite the estimated figure of 4.97 B MXN. In the next quarter, revenue is expected to reach 6.05 B MXN.
HALO net income for the last quarter is 2.70 B MXN, while the quarter before that showed 1.71 B MXN of net income which accounts for 57.85% change. Track more HALOZYME THERAPEUTICS, INC financial stats to get the full picture.
No, HALO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 28, 2024, the company has 373.00 employees. See our rating of the largest employees — is HALOZYME THERAPEUTICS, INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HALOZYME THERAPEUTICS, INC EBITDA is 11.01 B MXN, and current EBITDA margin is 50.94%. See more stats in HALOZYME THERAPEUTICS, INC financial statements.
Like other stocks, HALO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HALOZYME THERAPEUTICS, INC stock right from TradingView charts — choose your broker and connect to your account.